ABT-263 (Navitoclax) 化学構造
分子量: 974.61

高品質保証

文献中の引用(35)

カスタマーフィードバック(13)

Quality Control & MSDS

製品説明

  • Compare Bcl-2 Inhibitors
    Bcl-2製品生物活性の比較
  • 研究分野

製品の説明

生物活性

製品説明 ABT-263(Navitoclax)は、 Bcl-xLBcl-2Bcl-w の強力な阻害剤で、Kiがそれぞれ ≤ 0.5 nM、≤1 nM 、≤ 1 nMです。
ターゲット

Bcl-xL

Bcl-2

Bcl-w

IC50

≤ 0.5 nM (Ki)

≤1 nM (Ki)

≤ 1 nM (Ki)[1]

In vitro試験 ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
EoL-1-cell NXXJdW82T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHhTWM2OD1yLkCwOlY6KM7:TR?= NXPSNIVDW0GQR1XS
MV-4-11 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwMEG1PFYh|ryP MU\TRW5ITVJ?
NKM-1 M{[yTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVT1fGlzUUN3ME2wMlAyPjl7IN88US=> NH3oNllUSU6JRWK=
ML-2 MkT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;nfGlEPTB;MD6wNVk5OyEQvF2= MoXmV2FPT0WU
BV-173 NHXEdnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGH1VIFKSzVyPUCuNFI{OTRizszN MWPTRW5ITVJ?
RS4-11 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTTTWM2OD1yLkCyOVg4KM7:TR?= Mn\3V2FPT0WU
HL-60 MonOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1:4O2lEPTB;MD6wNlkxQCEQvF2= NYrrNo5wW0GQR1XS
KY821 NFPrV3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjBT3lSUUN3ME2wMlAzQTd3IN88US=> MnqwV2FPT0WU
ECC10 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFSy[|hKSzVyPUCuNFM4QTJizszN MoD4V2FPT0WU
NCI-H720 NF3OfmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXKOYtKSzVyPUCuNFQxOTFizszN MVfTRW5ITVJ?
QIMR-WIL NY\2dnNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnz6TWM2OD1yLkC0Nlg4KM7:TR?= MYTTRW5ITVJ?
KG-1 M{HWU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoW0TWM2OD1yLkC0OFg3KM7:TR?= MV;TRW5ITVJ?
TGW MlLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4L4TGlEPTB;MD6wOFY{OyEQvF2= NYLININZW0GQR1XS
ATN-1 MmfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33lPGlEPTB;MD6wOFc{OyEQvF2= MnjwV2FPT0WU
RH-18 NYPic4tNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHe5ZZlKSzVyPUCuNFYxPDhizszN NFPI[llUSU6JRWK=
EW-18 MnHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTBwME[4OFEh|ryP NIjTbW5USU6JRWK=
NB17 M4jSSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4niOWlEPTB;MD6wO|EzPCEQvF2= M4PjW3NCVkeHUh?=
SK-NEP-1 NX3KcnQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NID0dlRKSzVyPUCuNFczOTNizszN NITIV4VUSU6JRWK=
P12-ICHIKAWA NETNc4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7uVXRKSzVyPUCuNFc4PzhizszN NXTQSXB[W0GQR1XS
KARPAS-45 M4PobGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTrTWM2OD1yLkC3PFE2KM7:TR?= NGTBS4pUSU6JRWK=
EW-3 M2DNTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwMEiwOVMh|ryP NXTCW2VLW0GQR1XS
NB13 NHPY[4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nMSmlEPTB;MD6wPFIxOyEQvF2= NU\ydWdwW0GQR1XS
NCI-H209 NH\NcXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXznVJZNUUN3ME2wMlA5PzB2IN88US=> MnzxV2FPT0WU
NCI-H1092 NYn0eGx6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfxWY5JUUN3ME2wMlExOjd3IN88US=> Mn\pV2FPT0WU
NH-12 Mon0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\ITWM2OD1yLkGwO|Q1KM7:TR?= M1zxUHNCVkeHUh?=
697 MojYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPLRnc5UUN3ME2wMlExQDN7IN88US=> M1LZUHNCVkeHUh?=
KE-37 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIn2ZmZKSzVyPUCuNVE{PyEQvF2= M2PoW3NCVkeHUh?=
MOLT-4 MlnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTBwMUWxOlkh|ryP NYXN[2NQW0GQR1XS
CHP-134 M2i5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fMRWlEPTB;MD6xOlMxPiEQvF2= MVPTRW5ITVJ?
D-283MED MlmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\NNmlEPTB;MD6xO|Y5PiEQvF2= NI\nN2NUSU6JRWK=
LU-135 M2O3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYezSXNFUUN3ME2wMlE5PTV{IN88US=> MojSV2FPT0WU
LU-134-A NHToS|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnr4TWM2OD1yLkG4OlcyKM7:TR?= MVvTRW5ITVJ?
EM-2 M33HOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fPeGlEPTB;MD6xPVkyQCEQvF2= NF\3NY1USU6JRWK=
LU-139 MoXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nobGlEPTB;MD6yNFQ6QCEQvF2= M{i0bHNCVkeHUh?=
ALL-PO NVXk[Y5HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwMkG5PFgh|ryP M3q0ZnNCVkeHUh?=
NB12 NVO2UJJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWT2NGNmUUN3ME2wMlI{OTF3IN88US=> NUHJRWR3W0GQR1XS
KP-N-YN NFjISJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Xqb2lEPTB;MD6yN|U4OyEQvF2= MWDTRW5ITVJ?
BEN NGm1fllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWL5bpk4UUN3ME2wMlI{QTZ6IN88US=> NHrJdYRUSU6JRWK=
HCC1569 NGD4dZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlq2TWM2OD1yLkK1NVA3KM7:TR?= MUXTRW5ITVJ?
HuO9 M13Ic2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVO3XplWUUN3ME2wMlI3PzF3IN88US=> M33VNXNCVkeHUh?=
WM-115 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHST2R6UUN3ME2wMlI4PzN6IN88US=> MkO2V2FPT0WU
CCRF-CEM MkmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwM{O1Nlkh|ryP NHztU2NUSU6JRWK=
IST-SL1 NGfUVpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjFTWM2OD1yLkO1N|Q{KM7:TR?= NYnEVI1lW0GQR1XS
BE-13 NFzYZXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTBwM{[0OVkh|ryP MWTTRW5ITVJ?
COR-L88 M13ZR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LOSWlEPTB;MD6zOlU1KM7:TR?= M1y3R3NCVkeHUh?=
DOHH-2 NUjWcYJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXZcJFKSzVyPUCuOFExOjNizszN MYDTRW5ITVJ?
A704 Mn3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjORWRKSzVyPUCuOFI3PyEQvF2= NGnDWXZUSU6JRWK=
KNS-81-FD NU\uU5d7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfGVld3UUN3ME2wMlQ1ODF5IN88US=> MVjTRW5ITVJ?
RPMI-8226 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1S3dGlEPTB;MD60OVY2OiEQvF2= M{\pd3NCVkeHUh?=
TGBC24TKB M2DTd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHm0VGNKSzVyPUCuOFU4PzhizszN M{HkfXNCVkeHUh?=
NCI-H1304 MmTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\KTWM2OD1yLkS2NVU4KM7:TR?= MUXTRW5ITVJ?
MOLT-13 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HrXWlEPTB;MD60OlYyOyEQvF2= NH65WHpUSU6JRWK=
EW-22 NXv3bGpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPUbnpKSzVyPUCuOFY3PzFizszN NX;jfYlYW0GQR1XS
MS-1 NYSzepI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHrT2ZKSzVyPUCuOFY6OzNizszN NXfvfVM5W0GQR1XS
RMG-I MnTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLYfmd6UUN3ME2wMlQ6PDZ2IN88US=> NUjpWHRSW0GQR1XS
NTERA-S-cl-D1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;meWlEPTB;MD61NFAyQSEQvF2= MYHTRW5ITVJ?
NCI-H1048 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwNUC5OVMh|ryP MmnIV2FPT0WU
SW1417 NGW3d4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFK1XW5KSzVyPUCuOVU1OzhizszN NWj5fYt2W0GQR1XS
DB MniyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LZ[mlEPTB;MD61O|A5KM7:TR?= M4LHOXNCVkeHUh?=
MEG-01 M13ZbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTBwNUizNkDPxE1? MmTkV2FPT0WU
EW-13 NEjabpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUG0[lNJUUN3ME2wMlU5OzRzIN88US=> MY\TRW5ITVJ?
LAMA-84 NHv0W4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTnS5NVUUN3ME2wMlU6OjB5IN88US=> MX\TRW5ITVJ?
J-RT3-T3-5 M{ntUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHvW5BYUUN3ME2wMlYxQDB6IN88US=> MmLFV2FPT0WU
MOLT-16 MoDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPQTHlKSzVyPUCuOlUzPjRizszN M3TabHNCVkeHUh?=
DU-4475 MmS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILHN5ZKSzVyPUCuOlU1OjdizszN MmT2V2FPT0WU
HAL-01 MoS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{i3RWlEPTB;MD63NlU1QSEQvF2= M2[1UXNCVkeHUh?=
RD NGPtSXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInETlFKSzVyPUCuO|U5QTlizszN NFvkU|BUSU6JRWK=
OAW-28 NWrxW4RzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzZU3M6UUN3ME2wMlc5OzdizszN M3yxU3NCVkeHUh?=
HCC38 MnuwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzmfItrUUN3ME2wMlgxOTlizszN NHLCfVZUSU6JRWK=
NMC-G1 NV74eYw{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnm5TWM2OD1yLkixNVIyKM7:TR?= MVvTRW5ITVJ?
EW-16 M2\pZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3X1RmlEPTB;MD64NVMzQCEQvF2= Mn;rV2FPT0WU
DU-145 NYnUcpF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTPWWl[UUN3ME2wMlg6QTJ|IN88US=> NHLudppUSU6JRWK=
HPAF-II NXnkfppTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2X0[GlEPTB;MD65NlYzQCEQvF2= Mn2zV2FPT0WU
A427 M1HwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjkRWlWUUN3ME2wMlk{ODJ{IN88US=> M4rzd3NCVkeHUh?=
PA-1 M{\sT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TNR2lEPTB;MD65OVY1OiEQvF2= NH;IfY5USU6JRWK=
OAW-42 NInzUVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXSTWM2OD1yLkm2NVQ3KM7:TR?= MW\TRW5ITVJ?
L-428 MoC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYi1[G05UUN3ME2xMlAyOjVizszN M3\LU3NCVkeHUh?=
COLO-824 NXjNXJk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXHTWM2OD1zLkCxO|A5KM7:TR?= MXPTRW5ITVJ?
P30-OHK MnjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLnNpdTUUN3ME2xMlA1Pjh6IN88US=> M3PaVHNCVkeHUh?=
NCI-H2170 NYDKc5ZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTSTWM2OD1zLkC2NlMh|ryP NU\yTYk3W0GQR1XS
HCC2998 MojZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTFwMEexN|Uh|ryP NFXNeodUSU6JRWK=
NB14 M1XjNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnwTWM2OD1zLkGzO|Q5KM7:TR?= NHnxPGZUSU6JRWK=
TGBC1TKB NIjIO2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfi[ZBKSzVyPUGuNVQyPTJizszN MlvUV2FPT0WU
KP-N-YS M4Htdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjpSoRxUUN3ME2xMlE3OjN4IN88US=> NU[5fWV5W0GQR1XS
CAL-120 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTFwMU[0Nlkh|ryP MnnjV2FPT0WU
SBC-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVT5NJJQUUN3ME2xMlE6ODV|IN88US=> MVfTRW5ITVJ?
C32 Mn7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknKTWM2OD1zLkG5NFg5KM7:TR?= NVy2ZYJkW0GQR1XS
HCC2157 M1nweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13BdmlEPTB;MT6xPVQ6PCEQvF2= NEXKe2NUSU6JRWK=
COLO-792 NVX1UnNCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTFwMkCwO|Eh|ryP NXzzUYh4W0GQR1XS
ES7 NF7B[HJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTO[VNKSzVyPUGuNlc6PTFizszN MVvTRW5ITVJ?
HEL NIXtOmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVT2XJlJUUN3ME2xMlMyODJ7IN88US=> NEjwV3NUSU6JRWK=
ES4 M2HlO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIr0fXZKSzVyPUGuN|Q6QThizszN NFrYTXRUSU6JRWK=
NCI-SNU-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTFwM{[1OVUh|ryP Mk\tV2FPT0WU
MDA-MB-415 MorHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7KNGVRUUN3ME2xMlM5QDVizszN NGSxN3ZUSU6JRWK=
NCI-H2342 MmHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\Fe2lEPTB;MT60NFI3QSEQvF2= Mnr4V2FPT0WU
NB69 Mn3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjETWM2OD1zLkS2NlcyKM7:TR?= NXfLd5NbW0GQR1XS
D-247MG MoHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTrNo9KSzVyPUGuOVEyOjJizszN NHfhUIlUSU6JRWK=
SCC-4 M1j4fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfURnBKSzVyPUGuOVk5QDdizszN NFr3WHBUSU6JRWK=
HuH-7 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWix[lk4UUN3ME2xMlY4Ojl|IN88US=> NX7VbHlIW0GQR1XS
A388 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4m0emlEPTB;MT62PFczPCEQvF2= MnHtV2FPT0WU
Calu-3 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPrcY1KSzVyPUGuO|A3QTdizszN M3S5TXNCVkeHUh?=
NCI-H1648 NX7rV5d[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDSTWM2OD1zLkexOFE5KM7:TR?= MkfDV2FPT0WU
NCI-H2052 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zM[2lEPTB;MT63NlIxOSEQvF2= NVrK[JpGW0GQR1XS
Ramos-2G6-4C10 NHvVTYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTMTWM2OD1zLkezOlU3KM7:TR?= Mm[1V2FPT0WU
DEL NIP0dYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnL0TWM2OD1zLke0OlkzKM7:TR?= M4TIcXNCVkeHUh?=
SNU-423 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PaT2lEPTB;MT63PFE2PyEQvF2= MWnTRW5ITVJ?
COR-L23 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTFwN{m4O|Qh|ryP M3i4c3NCVkeHUh?=
OMC-1 NELtOGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vyeGlEPTB;MT64OlAyPiEQvF2= MkjkV2FPT0WU
EW-11 NIDzSGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XIZWlEPTB;MT65OVY2PyEQvF2= MXLTRW5ITVJ?
HSC-3 NYnsSnE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTFwOU[zOlUh|ryP MWrTRW5ITVJ?
MLMA M17hfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTFwOU[2O|ch|ryP NHjEZ5JUSU6JRWK=
RCM-1 M{PYZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTJwMECzPVkh|ryP NVPLTVd7W0GQR1XS
MFE-280 NUmxenB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLnVFVKSzVyPUKuNFI5PDhizszN MWPTRW5ITVJ?
ES8 NW[4SHNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnhOJRKSzVyPUKuNlU1PzFizszN NXn5bHp2W0GQR1XS
TE-11 M{jZTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHxSHdHUUN3ME2yMlI6PDd|IN88US=> M{HVR3NCVkeHUh?=
HuO-3N1 NXTsUIlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTJwNEi3PEDPxE1? MXnTRW5ITVJ?
MHH-NB-11 M4HrXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljSTWM2OD1{LkWxNVU5KM7:TR?= NYrJ[IVSW0GQR1XS
TGBC11TKB M4\JTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTJwNUe2PFEh|ryP MULTRW5ITVJ?
HOP-92 NFfhOZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\sdJVKSzVyPUKuOVg4PDNizszN MYTTRW5ITVJ?
IGR-1 NVLtfoFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jYcGlEPTB;Mj62NlA{PSEQvF2= NECxR2lUSU6JRWK=
GOTO MkfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTJwNkWzO|ch|ryP M3TXWXNCVkeHUh?=
NCI-H1650 MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTJwN{KyNVUh|ryP M4WyeXNCVkeHUh?=
NCI-H1581 NFPUUWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrDXGRKSzVyPUKuO|k3QDFizszN M3LO[3NCVkeHUh?=
NCI-H2405 M4XoWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rMZWlEPTB;Mj64Nlc5OiEQvF2= MWPTRW5ITVJ?
U-118-MG NGTvbHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\GR2pKSzVyPUKuPVY1QTFizszN MXnTRW5ITVJ?
DoTc2-4510 MnKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7hV21KSzVyPUOuNFE1OTdizszN MYnTRW5ITVJ?
NCI-H596 NVrm[lFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTNwMES5PVch|ryP M3rZV3NCVkeHUh?=
MPP-89 NInOXoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXziV5czUUN3ME2zMlA2PjZ4IN88US=> MkTLV2FPT0WU
GCIY NGDyWZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTNwMkC0PVEh|ryP NHv1VW1USU6JRWK=
SW626 NFe5cJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4H6eGlEPTB;Mz6yOFU1OyEQvF2= NYHPRXg4W0GQR1XS
OCI-AML2 MmDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37ENWlEPTB;Mz6zNVI4OiEQvF2= NInqZXdUSU6JRWK=
NBsusSR NEHrdXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPxTWM2OD1|LkO0PVM5KM7:TR?= M{HHVnNCVkeHUh?=
AN3-CA NFzJc5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTNwNESyN|gh|ryP MWfTRW5ITVJ?
EFM-19 NUXBXnpST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTNwNEizN|kh|ryP MUXTRW5ITVJ?
RVH-421 M1;1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLDNHVbUUN3ME2zMlU3QDd5IN88US=> M{TFUnNCVkeHUh?=
5637 NFrjVo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TzRWlEPTB;Mz62NVExOyEQvF2= M1XyVHNCVkeHUh?=
PANC-08-13 M2rlR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17r[2lEPTB;Mz62N|Q4OiEQvF2= NGHKbYpUSU6JRWK=
H9 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTmTWM2OD1|Lk[3NVQ1KM7:TR?= M1vvVHNCVkeHUh?=
KARPAS-299 Mny0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7WZVBrUUN3ME2zMlY4OzZzIN88US=> M2OxSXNCVkeHUh?=
TE-5 NX;TRoJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTNwN{C3NFkh|ryP NV;aO|dYW0GQR1XS
NOS-1 NXL3SmR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3faNWlEPTB;Mz63PVg{PCEQvF2= MkLKV2FPT0WU
HH NYfWXXo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13zT2lEPTB;Mz64N|g3QCEQvF2= MWLTRW5ITVJ?
769-P M3j3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTNwOEm1NUDPxE1? M1zVWXNCVkeHUh?=
CHP-212 NUO5VpZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHjXZRKSzVyPUOuPVI2PDlizszN M1[ydXNCVkeHUh?=
NCI-H82 MlL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTwTWM2OD1|Lkm1PVM3KM7:TR?= M1jzd3NCVkeHUh?=
Mo-T MnP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1WzWGlEPTB;ND6wOFMyOiEQvF2= NXHRTG1vW0GQR1XS
BB65-RCC MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTRwMESzPVkh|ryP NF\VOFZUSU6JRWK=
SW1990 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTRwMEW5NFgh|ryP MkHaV2FPT0WU
LK-2 Ml;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTRwMUGyPVMh|ryP NUHGTWZlW0GQR1XS
ES5 NYmxS5hTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDKTWM2OD12LkGzPVg2KM7:TR?= NXTie3NNW0GQR1XS
JVM-3 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUf2W3p5UUN3ME20MlE5OjJ{IN88US=> NYX4VmI1W0GQR1XS
RPMI-7951 M4jWTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTRwMkK0NVMh|ryP MXHTRW5ITVJ?
Calu-6 NFXx[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPaTWM2OD12LkK3PFgyKM7:TR?= MkCyV2FPT0WU
LC-2-ad M2CydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTRwMkm1Olgh|ryP M2DRN3NCVkeHUh?=
SW954 M1Twemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnNcnhKSzVyPUSuNlk3PiEQvF2= NF[xVoZUSU6JRWK=
H-EMC-SS MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LINmlEPTB;ND6zNVg{OSEQvF2= NGPKdlRUSU6JRWK=
ES3 NV62[JFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUX4fYxjUUN3ME20MlM2PDRzIN88US=> NWno[GJiW0GQR1XS
no-11 NWLVWJpzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HkTGlEPTB;ND6zOVU2PCEQvF2= MWLTRW5ITVJ?
LAN-6 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTRwNEWxPFkh|ryP M{\IUXNCVkeHUh?=
FTC-133 NXf3fm9jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTkXJRKSzVyPUSuOVM6PSEQvF2= M{H1d3NCVkeHUh?=
8505C NIDMcWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTRwNUSyN{DPxE1? MX;TRW5ITVJ?
SW620 NUK4OIZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rPW2lEPTB;ND61O|A2PyEQvF2= NVm0SmhoW0GQR1XS
BCPAP NFPlbmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTRwNkO0PFEh|ryP NVrscZoxW0GQR1XS
SK-LU-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jwUGlEPTB;ND62OlA5QSEQvF2= MUTTRW5ITVJ?
NCI-H1623 NVe2b4VPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTRwN{CyNlgh|ryP NVvyUnZOW0GQR1XS
C2BBe1 NYLq[WxnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{X6O2lEPTB;ND63OFAxQCEQvF2= MYrTRW5ITVJ?
GP5d NELTbXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17XRmlEPTB;ND63PFM5QCEQvF2= NX3JdnBNW0GQR1XS
NB6 MlnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fvN2lEPTB;ND64OlIxPCEQvF2= NUP3UGhFW0GQR1XS
MDA-MB-157 NHLpbI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnybY1KSzVyPUSuPFg4PiEQvF2= MWDTRW5ITVJ?
UMC-11 MoXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7jPHoyUUN3ME20Mlg5QTZ2IN88US=> MlfHV2FPT0WU
HCC1419 NVr3RZJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTRwOUCwOlMh|ryP M3TJcXNCVkeHUh?=
NCI-H2029 M1[zTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoC5TWM2OD12Lkm0NVg2KM7:TR?= NGrjcIJUSU6JRWK=
LXF-289 M1e4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;NTWM2OD13LkCzO|E6KM7:TR?= NX7OcngzW0GQR1XS
KINGS-1 NFTCXHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHtTWM2OD13LkC3O|Q1KM7:TR?= MXfTRW5ITVJ?
HD-MY-Z NGLhfXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHDSJlDUUN3ME21MlI{QTZ7IN88US=> MXfTRW5ITVJ?
ESS-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVn5fWJSUUN3ME21MlI2PTl5IN88US=> MXfTRW5ITVJ?
GI-1 NEfsbmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NES4fopKSzVyPUWuNlc6OjZizszN MnfIV2FPT0WU
RPMI-2650 NWfmZolST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHpTWM2OD13LkO2NVYh|ryP MVLTRW5ITVJ?
IA-LM MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HqWmlEPTB;NT6zPVg4OSEQvF2= NXjZXYlOW0GQR1XS
KP-4 M4f6UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXGdnlKSzVyPUWuOFY{OzRizszN NGDzZolUSU6JRWK=
G-402 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfLbpN1UUN3ME21MlUyQDZ3IN88US=> MX3TRW5ITVJ?
OS-RC-2 NFfmU5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PrOWlEPTB;NT61NlYxPCEQvF2= M3ztPHNCVkeHUh?=
NCI-H1155 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3WbnVTUUN3ME21MlU1QTV3IN88US=> NIOyd5BUSU6JRWK=
OE19 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmOxTWM2OD13Lk[4OlI1KM7:TR?= MUHTRW5ITVJ?
U-2-OS MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;JOmlEPTB;NT64PVAyOyEQvF2= NXyzOmliW0GQR1XS
SCC-15 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIS3VVRKSzVyPUWuPVM3PjJizszN NYTOSnJ[W0GQR1XS
NCI-H630 NHvP[IlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzaWZBqUUN3ME21Mlk6PDB2IN88US=> MVXTRW5ITVJ?
PFSK-1 NWPSRpl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHLZmpKSzVyPU[uNFUzPTlizszN NHjSbJdUSU6JRWK=
NCI-H1770 MnPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33ROWlEPTB;Nj6yNFg4PCEQvF2= M2C5NHNCVkeHUh?=
SK-MEL-3 NFO4bINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mom5TWM2OD14LkSyPVE2KM7:TR?= NITxW2tUSU6JRWK=
LB1047-RCC MkDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mon1TWM2OD14LkS3OlI2KM7:TR?= NYLLOGFPW0GQR1XS
NCI-H446 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PlemlEPTB;Nj62NlkzPSEQvF2= MnnuV2FPT0WU
SW780 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTZwN{CxPFUh|ryP MojLV2FPT0WU
NEC8 M1LZOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2D4R2lEPTB;Nj63OlY{KM7:TR?= MUTTRW5ITVJ?
NOMO-1 M{Hze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInxTVBKSzVyPU[uO|gyOTFizszN MmnpV2FPT0WU
COLO-668 NEfSeFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXselBQUUN3ME22Mlg1Ozh5IN88US=> NUfVe3M6W0GQR1XS
MC116 M2G4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnLXo5KSzVyPU[uPVM5QTdizszN MX3TRW5ITVJ?
HCC1937 MofsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTZwOUmyOVEh|ryP MVvTRW5ITVJ?
NCI-N87 NX\2W5F[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7KTWM2OD15LkG5Nlk{KM7:TR?= MV\TRW5ITVJ?
COLO-320-HSR M2PnTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLScYZKSzVyPUeuNlI4OzhizszN MmnXV2FPT0WU
HCC1806 M1\1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vBSmlEPTB;Nz6yOlA1PCEQvF2= M1P6eHNCVkeHUh?=
OVCAR-3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHGVGtRUUN3ME23MlM{ODN6IN88US=> NHHGU4pUSU6JRWK=
NUGC-3 NF2wfIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPaTWM2OD15LkO5Olk1KM7:TR?= M3jBPHNCVkeHUh?=
SW1783 Mnr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTGcI9IUUN3ME23MlQ{OTd3IN88US=> M1TjbnNCVkeHUh?=
GCT MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\GWIFsUUN3ME23MlU3QTB4IN88US=> MX7TRW5ITVJ?
NCI-H2126 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVva[o9EUUN3ME23Mlc{PjJ3IN88US=> Ml;NV2FPT0WU
MEL-HO MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXobWVKSzVyPUeuO|cxPTRizszN NWPLb5BqW0GQR1XS
CAPAN-1 NYK1PWh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\sdGlEPTB;Nz63O|M2PyEQvF2= NV;yUmozW0GQR1XS
SW756 NVThVmpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnqTJdtUUN3ME23Mlc5OzN|IN88US=> NVrBRo4xW0GQR1XS
SKG-IIIa MnviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnr0TWM2OD15LkixPFkzKM7:TR?= NGXWfJFUSU6JRWK=
HCE-T M2nUdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTdwOEe3PFMh|ryP M3rNXnNCVkeHUh?=
Ca-Ski NXXKfoxWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTdwOUmzPFMh|ryP M4rs[nNCVkeHUh?=
COLO-684 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTHTWM2OD16LkCxPFE5KM7:TR?= NYnYPG1MW0GQR1XS
KYSE-70 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jUNGlEPTB;OD6wO|czQSEQvF2= MUnTRW5ITVJ?
TI-73 MkKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRThwMkW4OVEh|ryP NFm5fI1USU6JRWK=
BT-20 NVL4Z|QzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvzTWM2OD16LkK2NFUzKM7:TR?= NYD0[|h5W0GQR1XS
MHH-ES-1 MkH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRThwNUG4N|Qh|ryP MkHOV2FPT0WU
TE-12 NX3HfXFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnBdGZKSzVyPUiuOVk6OzFizszN MYLTRW5ITVJ?
YH-13 M1[4ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHkdplsUUN3ME24MlYyODB6IN88US=> NHXaeFVUSU6JRWK=
SF126 NV:ybnk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoCyTWM2OD16LkizPFY2KM7:TR?= MmPPV2FPT0WU
J82 NGjsSYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLRTWM2OD16LkmwNFM5KM7:TR?= NHnVRZBUSU6JRWK=
RCC10RGB NXfvfnF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfp[2pKSzVyPUiuPVk2PjFizszN MVHTRW5ITVJ?
SK-UT-1 NFLWT3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofxTWM2OD17LkC0PVQ2KM7:TR?= M1jOTnNCVkeHUh?=
LB2241-RCC NIrUOopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfwOpBrUUN3ME25MlE6OTN5IN88US=> MVrTRW5ITVJ?
LB996-RCC MmHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTlwMUm4PUDPxE1? MUfTRW5ITVJ?
EPLC-272H MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTlwM{e2OVch|ryP NUfp[ZZKW0GQR1XS
CTV-1 MoPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PYPGlEPTB;OT61OlU{OiEQvF2= MU\TRW5ITVJ?
HSC-2 M{PoTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTlwNUe1OUDPxE1? M3XYNXNCVkeHUh?=
SK-MEL-28 M{XqcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDFTWM2OD17Lk[xPFk{KM7:TR?= NUPyW5dRW0GQR1XS
MMAC-SF MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXpTWM2OD17Lk[4O|Uh|ryP MV7TRW5ITVJ?
CP50-MEL-B NFSyOmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTlwN{W3PFIh|ryP MmC4V2FPT0WU
HT-1080 MoH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;VfZpKSzVyPUmuO|c4OzlizszN MkXXV2FPT0WU
HEC-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkm0TWM2OD1zMD6zN|UzKM7:TR?= MorMV2FPT0WU
AGS MofxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTFyLkO3OEDPxE1? M3LsTHNCVkeHUh?=
GAMG MlPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV[zW5VCUUN3ME2xNE42OTZ{IN88US=> MnfjV2FPT0WU
SW48 NIfwN5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTFyLkWxPFkh|ryP M3;I[nNCVkeHUh?=
U031 MmfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLIZop3UUN3ME2xNE42QTB6IN88US=> NHPveHBUSU6JRWK=
OVCAR-5 NEX5fpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Ty[WlEPTB;MUCuOlQzQSEQvF2= NG\YXlVUSU6JRWK=
SF295 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7zTWM2OD1zMD62O|A1KM7:TR?= M33wbnNCVkeHUh?=
BHT-101 NUfaR|R{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnyTWM2OD1zMD63NVc4KM7:TR?= MUDTRW5ITVJ?
VMRC-RCZ NVjZZZlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTFzLkOyNFEh|ryP NIH4NmtUSU6JRWK=
ACHN M4W1OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M170ZmlEPTB;MUGuOFIyOSEQvF2= MlPlV2FPT0WU
NCI-H526 NXv6UmpRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PSNGlEPTB;MUGuOVA1OyEQvF2= NXzWRZZTW0GQR1XS
MN-60 Moj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnIcJNKSzVyPUGxMlU{QSEQvF2= NYXoZlMyW0GQR1XS
NCI-H2291 MmrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXj6eItlUUN3ME2xNU42PDZ4IN88US=> M{PObnNCVkeHUh?=
SCC-25 MkS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2roWGlEPTB;MUGuO|U2PiEQvF2= M1e5fnNCVkeHUh?=
SK-MEL-2 M1fvUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvaTWM2OD1zMT63OlM4KM7:TR?= MWLTRW5ITVJ?
SN12C Mk\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfOZo5KSzVyPUGxMlk{PTVizszN MnjBV2FPT0WU
NCI-H69 M4Hq[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTF{LkSyN|Qh|ryP NFS1PWNUSU6JRWK=
ME-180 NVu4Z5Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHxdo92UUN3ME2xNk44ODV2IN88US=> MUfTRW5ITVJ?
MC-IXC NEL3fZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGiwWXNKSzVyPUGyMlc2OThizszN MVPTRW5ITVJ?
NCI-H2347 M1jYbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTqW4hqUUN3ME2xNk44PjF2IN88US=> M3XHbHNCVkeHUh?=
M059J NFTXeFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4C4b2lEPTB;MUKuO|czPyEQvF2= M2jmRnNCVkeHUh?=
A2058 NUnYT4JkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTF{Lki2PFEh|ryP M3LnTXNCVkeHUh?=
VA-ES-BJ M2T6dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jze2lEPTB;MUKuPFc5PSEQvF2= MVfTRW5ITVJ?
Ca9-22 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIT3SJdKSzVyPUGyMlk1PTFizszN NIfHWWxUSU6JRWK=
KNS-42 M{X5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfWXG5GUUN3ME2xNk46QTh2IN88US=> NX\1d49SW0GQR1XS
LoVo MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PWOGlEPTB;MUOuNlMyOyEQvF2= NVPZRXdPW0GQR1XS
AM-38 NET6fJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jWPWlEPTB;MUOuNlU3PiEQvF2= NU\2Sow2W0GQR1XS
NB5 MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvxTWM2OD1zMz6zO|UzKM7:TR?= M3vtOnNCVkeHUh?=
L-363 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTF|LkSwN|Mh|ryP NHGxZ45USU6JRWK=
SK-MEL-30 NHv4OYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3qWmVKSzVyPUG0MlA3PDVizszN MWPTRW5ITVJ?
NCI-H1563 NUD0WZNFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzIWWxKSzVyPUG0MlYxOzlizszN Mn;PV2FPT0WU
NCI-H2228 NWDp[Zo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3ITFNJUUN3ME2xOE43ODd5IN88US=> NF\JcHNUSU6JRWK=
MFM-223 M1z0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTF3LkG4NVMh|ryP Ml:4V2FPT0WU
LB831-BLC NVzWcJBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfJTlVKSzVyPUG1MlI4PjdizszN NX7XUnp5W0GQR1XS
SW872 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fISmlEPTB;MUWuN|A5PiEQvF2= MUDTRW5ITVJ?
NCI-H522 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvac|M6UUN3ME2xOU4{OzB4IN88US=> M3LhZnNCVkeHUh?=
EW-1 NUjUWIozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTF3LkW0OlIh|ryP NHvtb4RUSU6JRWK=
HN MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\JSGRKSzVyPUG1MlU6PDJizszN NU\GbIt4W0GQR1XS
SW837 NXToVGR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;3TWM2OD1zNT63PFQ4KM7:TR?= Mo\RV2FPT0WU
SCC-9 NFzOVpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXtOmxKSzVyPUG1MlgyOTRizszN NFrqcWRUSU6JRWK=
MKN7 M{HMXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfjOXhmUUN3ME2xOU46PzN{IN88US=> M4j1[3NCVkeHUh?=
KYSE-410 Mlm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDFcXlxUUN3ME2xOk42QTFizszN MmPYV2FPT0WU
SK-N-DZ MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGj6b3dKSzVyPUG2MlYyOTZizszN NULEVWF1W0GQR1XS
COR-L105 M1fxZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\vdpJVUUN3ME2xOk43PTJ6IN88US=> NX\P[otXW0GQR1XS
LB2518-MEL MoixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHYWnJKSzVyPUG2Mlg{QDlizszN NX;GPVRTW0GQR1XS
OVCAR-4 M3zJTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTF4Lki4OlIh|ryP M{LkXnNCVkeHUh?=
TK10 NVHxbGpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXoOVdKSzVyPUG2Mlk1PzNizszN NIroZXVUSU6JRWK=
KNS-62 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnP2TWM2OD1zNj65O|c4KM7:TR?= NHr4cZJUSU6JRWK=
RPMI-8866 NGL5b2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTF5LkG3N|Ih|ryP MV3TRW5ITVJ?
HuP-T4 NULvZZlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\tNlJKSzVyPUG3MlI1QTVizszN MlnSV2FPT0WU
CGTH-W-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;JfXhKSzVyPUG3MlUzOTlizszN NVW5fHZSW0GQR1XS
T-24 NWnxRolLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLZTWM2OD1zNz61N|Q4KM7:TR?= NIrCO2dUSU6JRWK=
HT-3 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTF5LkW5NVQh|ryP M3XDXHNCVkeHUh?=
KS-1 M4T4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfDZmF5UUN3ME2xO{43PzNizszN NWHRUYVEW0GQR1XS
NCI-H1792 M4rndmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLCSoh{UUN3ME2xO{44QThizszN M3S0TXNCVkeHUh?=
ABC-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;oWVZKSzVyPUG3MlgyPDFizszN NH;CT4hUSU6JRWK=
BPH-1 NH\w[3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVu3bVhyUUN3ME2xPE4yPjh3IN88US=> NE\0WoxUSU6JRWK=
A431 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlyxTWM2OD1zOD60NVI4KM7:TR?= Mn31V2FPT0WU
T98G M{jv[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XGXGlEPTB;MUiuOVE2PyEQvF2= Ml2yV2FPT0WU
BHY MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTF6Lki2PUDPxE1? MkT0V2FPT0WU
Capan-2 NF21b4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jSUWlEPTB;MUiuPVA4QCEQvF2= MmfTV2FPT0WU
MDA-MB-175-VII NF\OU25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PH[mlEPTB;MUiuPVIxQSEQvF2= NHvvTHNUSU6JRWK=
CAL-27 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDLZ3RKSzVyPUG5MlA1QDdizszN NXT3R5lWW0GQR1XS
AsPC-1 MoC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHyS|ExUUN3ME2xPU45PjV5IN88US=> NVLXVmUzW0GQR1XS
KU812 MkLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTF7Lkm1O|Mh|ryP NH;weJVUSU6JRWK=
NCI-H441 NHTUVFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vW[mlEPTB;MkCuNFAyKM7:TR?= M4G4fHNCVkeHUh?=
Mewo Mlf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH24cnZKSzVyPUKwMlEzQDhizszN NUnBcm1{W0GQR1XS
SK-MEL-24 NED5SIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTJyLkG0O|ch|ryP MnrDV2FPT0WU
NCI-H727 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPDWHBKSzVyPUKwMlI4ODRizszN MoLkV2FPT0WU
EKVX NGnTSIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\3WWlEPTB;MkCuOlA3KM7:TR?= Ml\UV2FPT0WU
RT-112 NHzlNHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWr6[XNDUUN3ME2yNE43OTJ{IN88US=> NFPOeo9USU6JRWK=
CAMA-1 NHznNolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvoVZVoUUN3ME2yNE46QDB|IN88US=> MX7TRW5ITVJ?
SW900 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnqVnJSUUN3ME2yNU4xOTR7IN88US=> NEnNSodUSU6JRWK=
NCI-H23 M3nRV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDPTnFKSzVyPUKxMlEzPzdizszN NFG0NpRUSU6JRWK=
SK-PN-DW M1fpSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVz1NFZLUUN3ME2yNU4yPjR7IN88US=> NXrwXnJHW0GQR1XS
BB30-HNC M{PHXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjSSZFKSzVyPUKxMlI4PDVizszN NH:xU3ZUSU6JRWK=
VM-CUB-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1uwVWlEPTB;MkGuN|U{PiEQvF2= M4XkfXNCVkeHUh?=
IST-MEL1 NEDrbHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHrTWM2OD1{MT6zOlkzKM7:TR?= NXHzSXE1W0GQR1XS
CTB-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXETXFKSzVyPUKxMlQ4PTVizszN NID0T|RUSU6JRWK=
LCLC-103H M1XNeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTOTWM2OD1{Mj6xOVgzKM7:TR?= MXXTRW5ITVJ?
PANC-03-27 M{\KUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PtdWlEPTB;MkKuOVE3QSEQvF2= MX;TRW5ITVJ?
HTC-C3 NYnNT3JPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTJ{LkW1OVUh|ryP NWnrW|hxW0GQR1XS
TE-8 Mon2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\wSWlEPTB;MkOuNlU3PSEQvF2= MYPTRW5ITVJ?
NCI-H292 M2LkUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTJ3LkO1N|Yh|ryP MX;TRW5ITVJ?
COLO-680N NV3GcYVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILQZY9KSzVyPUK1MlY{OjlizszN MWjTRW5ITVJ?
KYSE-520 Mk\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHq1b|BKSzVyPUK1MlY1PCEQvF2= M4jZWXNCVkeHUh?=
NB10 Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTJ4LkOxNVch|ryP MoTGV2FPT0WU
NCI-H661 NIjmOIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnv6TWM2OD1{Nj60O|E{KM7:TR?= MV;TRW5ITVJ?
GMS-10 M2HWZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LlV2lEPTB;Mk[uPFY{QCEQvF2= MoPUV2FPT0WU
NCI-H2122 NEP6UpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7kXVMxUUN3ME2yOk46QTl6IN88US=> MkDvV2FPT0WU
OVCAR-8 MoLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HxV2lEPTB;MkeuNFY{QCEQvF2= MorXV2FPT0WU
DJM-1 NVvXZ3pVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTJ5LkG0OVQh|ryP MV;TRW5ITVJ?
UACC-893 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYP4TmhGUUN3ME2yO{46QDd6IN88US=> M3nJWHNCVkeHUh?=
C8166 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTJ6Lk[5N|gh|ryP NEi2PXlUSU6JRWK=
NCI-H1693 MoTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\G[JVoUUN3ME2yPE43QTd3IN88US=> NUHxdXFYW0GQR1XS
TYK-nu NVnZVoZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTNyLkCzOFUh|ryP MXTTRW5ITVJ?
SW1710 MmiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnhTWM2OD1|MD6xNlYh|ryP NYjXfW5NW0GQR1XS
A375 M1XyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHKy[JNKSzVyPUOwMlMzPDNizszN MnqzV2FPT0WU
HMV-II MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTNzLkO1PVIh|ryP MWfTRW5ITVJ?
NCI-H2087 Ml33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnZTWM2OD1|MT62N|UzKM7:TR?= NWjOPHUyW0GQR1XS
CAL-54 M3rVfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTNzLkeyOFEh|ryP NF7Dd41USU6JRWK=
HCC70 NWezOIpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{H2[GlEPTB;M{KuNVM5PyEQvF2= MVrTRW5ITVJ?
ES1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkj0TWM2OD1|Mj6zNFYzKM7:TR?= NHnDW3FUSU6JRWK=
NCI-H1355 NFOwPVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LrSmlEPTB;M{OuNlA1KM7:TR?= M2TTOnNCVkeHUh?=
CFPAC-1 MlG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3ITWM2OD1|Mz6yN|MzKM7:TR?= NW\3d3Z4W0GQR1XS
MKN28 MkfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoX0TWM2OD1|Mz6zPFA6KM7:TR?= Mln6V2FPT0WU
HDLM-2 M3XaS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHW4XoNKSzVyPUOzMlY6OzFizszN M3OzNXNCVkeHUh?=
PANC-10-05 NWe1T5BQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnBTW1KSzVyPUO0MlExOTRizszN M4\tXnNCVkeHUh?=
SAS NWDqdVVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXocHRCUUN3ME2zOE41PTZ3IN88US=> NFW5VnpUSU6JRWK=
HCC1395 M3\SUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH[4R4tKSzVyPUO0MlcyQDZizszN NVHtZmREW0GQR1XS
8305C Mn7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml34TWM2OD1|NT64OFE2KM7:TR?= NYn1XFYyW0GQR1XS
KM12 M{W0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTN4Lke1OFch|ryP M2GwRnNCVkeHUh?=
SW1116 MmTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3G4W2lEPTB;M{euOVk6OiEQvF2= NYq5W|BCW0GQR1XS
SK-MEL-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3L5c2lEPTB;M{iuN|M5QSEQvF2= MYTTRW5ITVJ?
HCC2218 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXez[lQ{UUN3ME2zPE43PTF7IN88US=> Ml\HV2FPT0WU
T84 MlT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fEd2lEPTB;M{iuO|QxQSEQvF2= NIPTNY1USU6JRWK=
ETK-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\LfWlKSzVyPUO5MlAzOiEQvF2= MoX2V2FPT0WU
COLO-800 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HxUWlEPTB;M{muN|g3QCEQvF2= NV3CSFBlW0GQR1XS
CAL-12T Mmj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4C0dWlEPTB;M{muOVI5OSEQvF2= MmnaV2FPT0WU
ACN NUPiTYx1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrFfXRKSzVyPUSwMlQ6OTFizszN NWXWeIdnW0GQR1XS
SJSA-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHyS4RoUUN3ME20NU4yPTl4IN88US=> NI\CV45USU6JRWK=
PSN1 NXXQcI46T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3VZ2lKSzVyPUSxMlE4PDlizszN M3zoWnNCVkeHUh?=
D-566MG NYjx[Vl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTRzLkKwPFYh|ryP MlfjV2FPT0WU
EGI-1 NF\z[45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXyTWM2OD12Mj60Nlgh|ryP NFSwW2lUSU6JRWK=
A204 MnjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml[4TWM2OD12Mj62N|g5KM7:TR?= MVTTRW5ITVJ?
Saos-2 Mm\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fJbmlEPTB;NEKuPFM3QSEQvF2= MkL3V2FPT0WU
SNU-C2B MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XYdGlEPTB;NEOuOlg4QCEQvF2= MV;TRW5ITVJ?
HLE MlL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW[2d|kzUUN3ME20OE4xQDV4IN88US=> NUTJWHJNW0GQR1XS
SW1463 M4DzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4m5V2lEPTB;NESuPVk4OSEQvF2= NIq4NnpUSU6JRWK=
DSH1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF2ySIhKSzVyPUS1MlAxOzNizszN M4LycXNCVkeHUh?=
MCF7 MmfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjsTpVKSzVyPUS1MlUxPTFizszN M4DiUHNCVkeHUh?=
K5 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3jPWJIUUN3ME20OU46PDB3IN88US=> M2LqeHNCVkeHUh?=
NCI-H358 NIW4R2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml[zTWM2OD12Nz6yNVUh|ryP NIS1VW9USU6JRWK=
NCI-H2030 NXT5PIt7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFK4UlVKSzVyPUS3MlI{PzRizszN NFL0NVlUSU6JRWK=
SW948 M{\me2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkCzTWM2OD12Nz60OlQh|ryP MnjtV2FPT0WU
BALL-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1G0WGlEPTB;NEeuOlE3QCEQvF2= NUfoNINxW0GQR1XS
TE-9 NFXhWWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTR5Lkm1PFEh|ryP MV3TRW5ITVJ?
SK-N-FI M{PvXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorHTWM2OD12OD6wN|U5KM7:TR?= MlftV2FPT0WU
KALS-1 NEXUWJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTR6LkGyPFkh|ryP NEPBR5NUSU6JRWK=
HO-1-N-1 MkPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPsZ3drUUN3ME20PE44PDR3IN88US=> M3PjUXNCVkeHUh?=
NCI-H2452 M{fUO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH[wfIFKSzVyPUS5MlEyPTJizszN MYXTRW5ITVJ?
OC-314 NUTUXm8{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPzPXRKSzVyPUS5MlY5OzRizszN NX;NUnlIW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo試験 When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]
臨床試験 ABT-263 is currently in Phase II clinical trial for the treatments of chronic lymphocytic leukemia.
特集

プロトコル (参考用のみ)

キナーゼアッセイ:

[1]

Affinity determination Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.

細胞アッセイ:

[1]

細胞株 SCLC cell lines
濃度 0-1 μM
反応時間 48 hours
実験の流れ

Human tumor cell lines SCLC cell lines are maintained at 37 °C containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.

動物実験:

[1]

動物モデル C.B.-17 scid-bg or C.B.-17 scid mice
製剤 Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
投薬量 100 mg/kg/d
投与方法 Administered via p.o.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download ABT-263 (Navitoclax) SDF
分子量 974.61
化学式

C47H55ClF3N5O6S3

CAS No. 923564-51-6
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 100 mg/mL (102.6 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 4-​[4-​[[2-​(4-​chlorophenyl)​-​5,​5-​dimethyl-​1-​cyclohexen-​1-​yl]​methyl]​-​1-​piperazinyl]​-​N-​[[4-​[[(1R)​-​3-​(4-​morpholinyl)​-​1-​[(phenylthio)​methyl]​propyl]​amino]​-​3-​[(trifluoromethyl)​sulfonyl]​phenyl]​sulfonyl]​-benzamide

カスタマーフィードバック (13)


Click to enlarge
Rating
Source , , J Clin Invest, 2014, 124(1): 117-28 . ABT-263 (Navitoclax) purchased from Selleck
Method Cell Viability Analysis
Cell Lines KP cells & A549 cells
Concentrations 300、500 nM
Incubation Time 96 h
Results KP mouse and A549 cells treated with a combination of ATN-224 and ABT-263 showed an increase in cell death compared with cells treated with ATN-224 alone.

Click to enlarge
Rating
Source , , Cell Death Differ, 2015, 10.1038/cdd.2015.73. ABT-263 (Navitoclax) purchased from Selleck
Method Cell Viability Analysis
Cell Lines NSC & Mcl-1 cells
Concentrations
Incubation Time 5 d
Results As seen with ABT-263, cells were largely resistant to compound alone but were extremely sensitive to combination with Mcl-1 silencing. In summary, the Bcl-xL inhibitors ABT-263 and WEHI-539 have an additive effect with Mcl-1 knockdown to reduce cell viabi眏Ỵ眐㠞眎膉癠 

Click to enlarge
Rating
Source Clin Cancer Res , 2010, 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck
Method Fluorescence polarization assay
Cell Lines
Concentrations 0.1-10 μmol/L
Incubation Time 4-12 h
Results To further characterize the nature of the binding of ABT-737 and ABT-263 to albumin, we used a fluorescence polarization assay.There are two main drug-binding sites on HSA: site 1 on subdomain IIA and site 2 on subdomain IIIA.Interestingly, ABT-263 displayed a markedly higher binding affinity to site 2 on HSA-III A than did ABT-737 (Fig. A). Whereas ABT-737 showed no binding to site 1, ABT-263 also bound to site 1 on HSA-IIA with an IC50 of 145 μmol/L (positive control phenylbutazone: 49 μmol/L; ref. 18; Fig. B) . These data show that ABT-263 has a higher albumin-binding capacity than does ABT-737, thus limiting the amount of free drug that is available to interact with the intended target, BCL2.

Click to enlarge
Rating
Source Clin Cancer Res, 2010, 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck
Method Fluorescein-dextran release assay/western blot
Cell Lines CLL cells
Concentrations 0-5 μmol/L
Incubation Time 1-2.5 h
Results One possible explanation for the reduced potency of ABT-263 compared with ABT-737 could be due to the former being inherently less potent. To investigate this possibility we compared their activities in a model biochemical system, using liposomes loaded with fluorescein-conjugated 10 kD dextran.The BCL-XL-mediated inhibition of liposome permeabilization was reversed in an a lmost identical concentration-dependent manner by both ABT-263 and ABT-737 (Fig. A). These results showed that both ABT-263 and ABT-737 targe t antiapoptotic BCL-XL with similar efficiency in this model liposome system containing only BCL2 family members but devoid of extraneous proteins. Another explanation for the lower potency of ABT-263 could be a lower plasma membrane permeability.we investigated the potential of ABT-737 and ABT-263 to induce cytochromec release from permeabilized CLL cells(Fig. B). ABT-737 was clearly more potentin inducing cytochrome c release from permeabilized cells.Taken together these results indicate that the reduced potential of ABT-263 to induce apoptosis cannot be explained solely by either differential plasma membrane permeability or by a lower potency of ABT-263 compared with ABT-737 to inhibit antiapoptotic BCL2 family members.

Click to enlarge
Rating
Source Clin Cancer Res, 2010, 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck
Method Mitochondrial membrane potential assay/Immunoprecipitation/electron microscopy/apoptosis assays
Cell Lines CLL cells/murine embryonic fibroblasts
Concentrations 10-100 nmol/L/0.3-30 μmol/L
Incubation Time 2-48 h
Results To gain in sight into the mechanism of ABT-263-induced cell death, we asked whether ABT-263 induced activation of apoptotic signaling pathways. ABT-263 induced a rapid cleavage of caspase-3 and loss of mitochondrial membrane potential, but was a gain less potent than ABT-737 ( Fig.A).To investigate the activity of both compounds at the level of BCL2 inhibition, we immunoprecipitated BCL2 upon drug treatment and measured the levels of BAK displaced by ABT-737 and ABT-263.BAK was shown to be associated with BCL2 (Fig. B). ABT-737 (10 or 100 nmol/L) efficiently d isplaced BAK from BCL2, whereas higher concentrations of ABT-263 (100 nmol /L) were required to induce release of BAK (Fig. B).ABT-263 (100 nmol/L) induced similar ultrastructural changes to ABT-737 (10 nmol/L), including condensed chromatin, rupture of the outer mitochondrial membrane, and loss of mitochondrial matrix d ensity (Fig. C).Finally, ABT-263-induced apoptosis was compl et ely inhibited in murine embryonic fibroblasts deficient for Bax and Bak (Fig. D), suggesting that ABT-263, like ABT-737 is a specific inhibitor of BCL2 proteins.

Click to enlarge
Rating
Source Clin Cancer Res, 2010, 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck
Method Apoptosis assays
Cell Lines CLL cells
Concentrations 1-1000 nmol/L
Incubation Time 4 h
Results In our study we identify two factors that affect the efficacy of the ABT-263: high cell density and plasma protein binding. In leukemic patients, the high circulating cell densities might contribute to the resistance of CLL cells to ABT-263 that we observed in whole blood as compared with standard cell culture (Fig. B).We also describe that the ABT-263 is extensively bound to albumin and that in the presence of albumin higher drug concentrations are required for apoptosis induction (Fig. D)

Click to enlarge
Rating
Source Clin Cancer Res, 2010, 16, 4217-4225. ABT-263 (Navitoclax) purchased from Selleck
Method Apoptosis assays
Cell Lines CLL cells
Concentrations 1-1000 nmol/L
Incubation Time 4 h
Results We compared the in vitro efficacy of two very closely related BCL2 antagon ists, ABT-737 and ABT-263. A direct comparison of the susceptibility of freshly isolated CLL cells to ABT-737 and ABT-263 in RPMI supplemented with 10% FCS revealed that both compounds induced efficient apoptosis but ABT-737 was∼4-fold more potent.

Click to enlarge
Rating
Source PLoS One, 2011, 6, e21980. ABT-263 (Navitoclax) purchased from Selleck
Method Hoechst staining/western blot
Cell Lines LH86 cells/Huh7 cells
Concentrations 0–20 μM
Incubation Time 24 h
Results The higher dose of ABT-263 (10–20 μM) treatment for 24 h induced significant DNA fragmentation and caspase 9 or 3 cleavage activation in HCC cells, whereas lower concentrations of ABT-263 (0–2.5 μM) had no apoptotic toxicity to HCC cells. These results suggest that HCC cells are relatively resistant to low doses of ABT-263.

Click to enlarge
Rating
Source PLoS One, 2011, 6, e21980. ABT-263 (Navitoclax) purchased from Selleck
Method Western blot/Hoechst staining/Apoptosis assays
Cell Lines LH86 cells
Concentrations 1 μM
Incubation Time 1-6 h
Results As shown in Figure A, the combination treatment of HCC cells with ABT-263 (1 μM) and YM-155 (1μM) for up to 6 h has no effects on the expressions of either anti-apoptotic protein Bcl-xL or pro-apoptotic proteins including Bad, Bak, and Bax. However, as expected, the presence of YM-155 significantly decreased survivin protein expression (Figure B, left third lane). Co-treatment of cells with ABT-263 (1 μM) and YM-155 (1μM) induced an even greater decrease in survivin protein expression (Figure B, right two lanes) than that of YM-155 itself did. However, we indeed observed that ABT-263 single treatment for 3 h resulted in survivin increase (Figure B). To further determine survivin inhibition plays a critical role in sensitizing ABT-263 to induce apoptosis in HCC cells, we down-regulated survivin expression in HCC cells by siRNA duplexes targeted against human survivin mRNA, and then examined the expression of survivin by Western blotting (Figure C) and apoptotic events after ABT-263 treatments. The results demonstrated that ABT-263 induced significant apoptosis in the survivin siRNA-transfected cells, but not in siRNA Random-transfected (control) cells (Figure D, E, and F).

Click to enlarge
Rating
Source PLoS One, 2011, 6, e21980. ABT-263 (Navitoclax) purchased from Selleck
Method Western blot/Hoechst staining
Cell Lines LH86 cells
Concentrations 1-2.5 μM
Incubation Time 1-24 h
Results Treatment of cells with ABT-263 (1-2.5 μM) for 1 h could result in the increase of phosphorylated ERK (p-ERK) but not ERK (Figure A). On the other hand, as shown in Figure B, ABT-263 (1 μM) administration could result in survivin expression increase. Thus, in an attempt to know if ERK-survivin activation could protect cells against ABT-263 toxicity, cells were untreated or treated with ABT-263 (1 μM), PD98059 (50 μM), or pre-treated with PD98059 (50 μM) followed by ABT-263 (1 μM). As shown in Figure C and D, blocking ERK activation with specific inhibitor PD98059 enhanced ABT-263-indcued apoptosis in HCC cells. To further determine ERK anti-apoptotic effects on ABT-263 treated HCC cells, we knocked down ERK expression through siRNA mediated gene silencing (Figure E) and then administrated ABT-263. Similar results revealed that ERK depletion sensitized ABT-263-induced apoptosis (Figure F). These results suggest the activation of ERK-survivin may render cells to be resistant to low dose ABT-263-induced apoptosis.

Click to enlarge
Rating
Source Biochem Biophys Res Commun, 2011, 408(2), 344-9. ABT-263 (Navitoclax) purchased from Selleck
Method Flow cytometry
Cell Lines MDCKII wild type cells/MDR1 cells
Concentrations 50 nM
Incubation Time 24 h
Results MDCKII cells transfected with MDR1 showed significantly less apoptosis inducedby ABT-737 (Fig. C) and ABT-263 (Fig. D) than wild type cells.

Click to enlarge
Rating
Source ABT-263 (Navitoclax) purchased from Selleck
Method Western Blotting/Co-Immunoprecipitation / Cell Death Experiments
Cell Lines Arf -null p185+ cells/ p185+ Arf-/- cells
Concentrations 0-1000nM
Incubation Time 24 h
Results As the navitoclax dose increased the amount of BCL-2 and BCL-X L immunoprecipitating with BIM decreased and there was a corresponding increase in MCL-1 protein associated with BIM (Fig. B). These data indicated that navitoclax displaced BIM from BCL-2 and BCL-XL and suggests that the liberated BIM could then interact with MCL-1 (Fig. B). As the navitoclax was increased we observed potentiation of the TKIs indicating a synergistic effect of combining navitoclax and TKI treatment (Fig. E&F).

Click to enlarge
Rating
Source ABT-263 (Navitoclax) purchased from Selleck
Method Western Blotting/Co-Immunoprecipitation / Cell Death Experiments
Cell Lines OP-1 Ph+ B-ALL cells/TOM1 Ph+ B-ALL cells/BV173 Ph+CML cells
Concentrations 0-60 nM
Incubation Time 24 h
Results As navitoclax was increased in the cultures we observed a potentiation of the TKIs to induce apoptosis. These data indicate that like our bservations in mouse BCR-ABL cell lines, combining TKIs and navitoclax in human Ph+ cell lines can also lead to enhanced activity. While MCL-1 expression is most overtly decreased in response to TKI treatment, it is possible that combining TKI and navitoclax may effect targets other than MCL-1 leading to cell death. These data suggest that combining TKIs and navitoclax may be effective in treating human Ph+ leukemia.

文献中の引用 (35)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related Bcl-2 阻害剤

  • A-1210477

    A-1210477 is a potent and selective MCL-1 inhibitor with Ki and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.

  • MI-773 (SAR405838)

    MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.

  • Venetoclax (ABT-199, GDC-0199)

    Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Kiof < 0.010 nM.

    Features:Re-engineered version of ABT-263 (Navitoclax).

  • ABT-737

    ABT-737は、Bcl-xL、Bcl-2とBcl-wのBH3模倣の阻害剤で、EC50 がそれぞれ78.7 nM、30.3 nM 、197.8 nMになる。

  • UMI-77

    UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.

  • Obatoclax Mesylate (GX15-070)

    Obatoclax Mesylate (GX15-070)は Bcl-2 を抑制して、 Kiが0.22 μMになる.

    Features:Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.

  • TW-37

    TW-37は、組み換え型Bcl-2(Bcl-xLとMcl-1)への新しい非ペプチド阻害剤で、Ki がそれぞれ 0.29 μM、1.11 μM、0.26 μMです。

  • Sabutoclax

    Sabutoclax is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.

  • AT101

    AT-101は、反アポトーシスのBcl-2 の強力な阻害剤であることを知られて、模倣のBH3家族です。

最近チェックしたアイテム

Tags: ABT-263 (Navitoclax)を買う | ABT-263 (Navitoclax)供給者 | ABT-263 (Navitoclax)を購入する | ABT-263 (Navitoclax)費用 | ABT-263 (Navitoclax)生産者 | オーダーABT-263 (Navitoclax) | ABT-263 (Navitoclax)代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ